Long-term metformin treatment in adolescents with obesity and insulin resistance, results of an open label extension study.

Autor:	Lentferink YE; Department of Pediatrics, St. Antonius Hospital, Nieuwegein/Utrecht, The Netherlands., van der Aa MP; Department of Pediatrics, St. Antonius Hospital, Nieuwegein/Utrecht, The Netherlands.; Kalkhaven, Gorinchem, The Netherlands., van Mill EGAH; Department of Pediatrics, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands., Knibbe CAJ; Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein/Utrecht, The Netherlands.; Division of Pharmacology, LACDR, Leiden University, Leiden, The Netherlands., van der Vorst MMJ; Department of Pediatrics, St. Antonius Hospital, Nieuwegein/Utrecht, The Netherlands. m.van.der.vorst@antoniusziekenhuis.nl.
Jazyk:	angličtina
Zdroj:	Nutrition & diabetes [Nutr Diabetes] 2018 Sep 10; Vol. 8 (1), pp. 47. Date of Electronic Publication: 2018 Sep 10.
DOI:	10.1038/s41387-018-0057-6
Abstrakt:	Background/objectives: Off-label metformin is nowadays frequently used for the treatment of obesity in adolescents. However, studies on long-term metformin treatment in adolescents with obesity are scarce. Therefore, an 18 month open label extension study following an 18 months randomized placebo-controlled trial (RCT) on the efficacy, safety, and tolerability of metformin in adolescents with obesity and insulin resistance was performed. Subjects/methods: After completion of the RCT, metformin was offered to all participants with a body mass index standard deviation score (BMI-sds) > 2.3 and Homeostasis Model Assessment for Insulin Resistance (HOMA-IR) ≥ 3.4. Endpoints were change in BMI and HOMA-IR. Results: Overall, 31/42 participants completed the extension study (74% girls, median age 14.8 (11.6 - 17.9), BMI 31.2 (22.3 - 45.1), HOMA-IR 3.4 (0.2 - 8.8)). At start, 22/42 (52.4%) participants were eligible for metformin of which 13 (59.0%) agreed with treatment. In participants who continued metformin, an increase was observed in BMI (+2.2 (+0.2 to +9.0)) and HOMA-IR (+13.7 (+1.6 to +48.3)). In metformin naive participants, BMI stabilized after an initial decrease (+0.5 (-2.1 to +5.1)). For HOMA-IR, a decrease was observed (-1.1 (-4.6 to +1.4)). Conclusion: While metformin treatment in metformin naive participants seems to result in an initial decrease in BMI and HOMA-IR, there is no evidence for sustained effect after prolonged use in adolescents. Limited compliance and/or insufficient dose may explain the differences in long-term effects between adolescents and adults.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu